How I treat patients who are refractory to platelet transfusions
Blood · 15.05.2025 · 145 (20) · 2293-2302
DOI: 10.1182/blood.2023022883 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Blood, erschienen am 15.05.2025. Verfasst von Susan Nahirniak und 2 weiteren Autor:innen. Beteiligte Einrichtung: Transfusion and Transplantation Medicine Program, Alberta Precision Laboratories, Alberta, Canada. Hauptthemen laut MEDLINE: Platelet Transfusion, Thrombocytopenia. Die Arbeit wurde bisher 19-mal zitiert (Crossref) und nennt 75 Literaturangaben.
Abstract (Originalsprache)
Patients with thrombocytopenia requiring ongoing platelet transfusion support may develop inadequate platelet count increments, referred to as platelet refractoriness (PR), which further complicates their care. The underlying etiologies of PR can be broadly divided into immune and nonimmune causes. A high index of suspicion is required to initiate testing for alloimmunization, and the leading culprit in immune PR is the development of class I HLA antibodies. The approach to diagnosis of immune PR has changed over recent years with new technologies, but questions regarding the clinical significance and interpretation of these methods have not been conclusively answered. The provision of HLA-matched platelets requires close and timely coordination between transfusion services and clinical teams; however, the true impact of their provision on clinical outcomes is not clear. This paper reviews diagnostic and management challenges, appraises the existing data available to support treatment options, and identifies research gaps.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Autor:innen und Institutionen
- Transfusion and Transplantation Medicine Program, Alberta Precision Laboratories, Alberta, Canada.
- Department of Laboratory Medicine and Pathology, Faculty of Medicine, University of Alberta, Edmonton, AB, Canada.
- Department of Preclinical Sciences, Faculty of Medicine and Health Sciences, Universiti Tunku Abdul Rahman, Kajang, Malaysia.
- Department of Haematology, Oxford University Hospitals NHS Foundation Trust, Oxford, United Kingdom.
- Radcliffe Department of Medicine, University of Oxford, Oxford, United Kingdom.
- NHS Blood and Transplant, Oxford, United Kingdom.
ORCID-Profile: Susan Nahirniak, Simon J Stanworth
Zitieren
APA
Nahirniak, S., Nadarajan, V., & Stanworth, S. J. (2025). How I treat patients who are refractory to platelet transfusions. Blood, 145(20), 2293-2302. https://doi.org/10.1182/blood.2023022883
Vancouver
Nahirniak S, Nadarajan V, Stanworth SJ. How I treat patients who are refractory to platelet transfusions. Blood. 2025;145(20):2293-2302. doi:10.1182/blood.2023022883
BibTeX
@article{Nahirniak2025,
author = {Nahirniak, Susan and Nadarajan, Veera and Stanworth, Simon J},
title = {How I treat patients who are refractory to platelet transfusions},
journal = {Blood},
year = {2025},
volume = {145},
number = {20},
pages = {2293--2302},
doi = {10.1182/blood.2023022883}
}
EUVIMED